



(51) International Patent Classification:

C12N 15/62 (2006.01) C07K 14/56 (2006.01)

(21) International Application Number:

PCT/US2021/026675

(22) International Filing Date:

09 April 2021 (09.04.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/008,542	10 April 2020 (10.04.2020)	US
63/161,889	16 March 2021 (16.03.2021)	US
63/164,849	23 March 2021 (23.03.2021)	US

(71) Applicant: **CYTOMX THERAPEUTICS, INC.**

[US/US]; 151 Oyster Point Boulevard, Suite 400, South San Francisco, California 94080 (US).

(72) Inventors: **MITRA, Sayantan**; 151 Oyster Point Boulevard, Suite 400, South San Francisco, California 94040 (US). **LAPUYADE, Nicole G.**; 151 Oyster Point Boulevard, Suite 400, South San Francisco, California 94080 (US). **ASSI, Hikmat Haizar**; 151 Oyster Point Boulevard, Suite 400, South San Francisco, California 94080 (US). **PAIDHUNGAT, Madan M.**; 151 Oyster Point Boulevard, Suite 400, South San Francisco, California 94080 (US). **DANIEL, Dylan D.**; 151 Oyster Point Boulevard, Suite 400, South San Francisco, California 94080 (US). **LE SCOLAN, Erwan**; 151 Oyster Point Boulevard, Suite 400, South San Francisco, California 94080 (US). **BOGDANOFF, Walter A.**; 151 Oyster Point Boulevard, Suite 400, South San Francisco, California 94080 (US). **CAI, Na**; 151 Oyster Point Boulevard, Suite 400, South San Francisco, California 94080 (US). **WANG, Hsin**; 151 Oyster Point Boulevard, Suite 400, South San Francisco, California 94080 (US).

(54) Title: ACTIVATABLE CYTOKINE CONSTRUCTS AND RELATED COMPOSITIONS AND METHODS




FIGURE 5

(57) **Abstract:** Provided herein are activatable cytokine constructs that include: (a) a first monomer construct comprising a first mature cytokine protein (CP1), a first cleavable moiety (CM1), and a first dimerization domain (DD1), wherein the CM1 is positioned between the CP1 and the DD1; and (b) a second monomer construct comprising a second mature cytokine protein (CP2), a second cleavable moiety (CM2), and a second dimerization domain (DD2), where the CM2 is positioned between the CP2 and the DD2, where: the CM1 and the CM2 function as a substrate for a protease; the DD1 and the DD2 bind each other; and where the ACC is characterized by a reduction in at least one activity of the CP1 and/or CP2 as compared to a control level of the at least one activity of the CP1 and/or CP2.



(74) **Agent:** HARSTON, Aydin H.; Rothwell, Figg, Ernst & Manbeck, P.C., 607 14th Street, NW, Suite 800, Washington, District of Columbia 20005 (US).

(81) **Designated States** (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) **Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))